Silence Therapeutics (NASDAQ:SLN) Posts Quarterly Earnings Results, Misses Expectations By $0.13 EPS

Silence Therapeutics (NASDAQ:SLN) issued its earnings results on Monday. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.13), FiscalAI reports. Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 105.34%.

Silence Therapeutics Stock Performance

Shares of Silence Therapeutics stock opened at $11.95 on Monday. The company has a market capitalization of $564.52 million, a P/E ratio of -7.52 and a beta of 1.39. The stock has a fifty day simple moving average of $9.31 and a 200 day simple moving average of $7.18. Silence Therapeutics has a 12-month low of $4.19 and a 12-month high of $12.31.

Institutional Trading of Silence Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. XTX Topco Ltd bought a new position in shares of Silence Therapeutics during the fourth quarter valued at about $71,000. Quadrature Capital Ltd bought a new position in shares of Silence Therapeutics during the 4th quarter worth approximately $331,000. Opaleye Management Inc. purchased a new position in shares of Silence Therapeutics in the 4th quarter worth approximately $480,000. Millennium Management LLC grew its holdings in shares of Silence Therapeutics by 121.0% in the fourth quarter. Millennium Management LLC now owns 659,592 shares of the company’s stock valued at $4,010,000 after acquiring an additional 361,080 shares in the last quarter. Finally, ADAR1 Capital Management LLC increased its position in shares of Silence Therapeutics by 26.8% during the fourth quarter. ADAR1 Capital Management LLC now owns 23,643 shares of the company’s stock valued at $144,000 after acquiring an additional 5,000 shares during the last quarter. Hedge funds and other institutional investors own 98.73% of the company’s stock.

Wall Street Analysts Forecast Growth

SLN has been the topic of several recent research reports. HC Wainwright reiterated a “buy” rating and issued a $75.00 price target on shares of Silence Therapeutics in a report on Wednesday, June 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Silence Therapeutics in a research report on Friday, July 17th. Finally, Cantor Fitzgerald initiated coverage on shares of Silence Therapeutics in a research report on Wednesday, June 24th. They issued an “overweight” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $75.00.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.